AUAUniversity

Co-Host: Vitaly Margulis, MD

At the conclusion of these activities, participants will be able to:

1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.

2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.

CME Available: https://auau.auanet.org/node/26079

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology. This one hour course is designed to improve clinicians’ understanding of current immunotherapeutic agents for the treatment of GU cancers, improve patient outcomes, and the management of adverse events. The course covers the following topics:

Immuno-Oncology: A Focus on Kidney Cancer

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Prostate Cancer

Managing Immune-Related Adverse Events

ACKNOWLEDGEMENTS

Independent educational grant support for the webcast and podcast provided by Merck & Co., Inc., Kenilworth, NJ, US

CME Available:

https://auau.auanet.org/content/therapeutic-advances-immuno-oncology-2019

Co-Host: William Huang, MD

At the conclusion of these activities, participants will be able to:

1. Discuss the current immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Identify and manage the adverse events related to these agents.

CME Available: auau.auanet.org/node/26095

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Take Home Messages: Female Urology/Incontinence

Ariana Smith, MD

University of Pennsylvania

Take Home Messages: Reconstruction

Giulia Lane, MD

Urology Fellow, FPMRS

University of Michigan

Co-Host: Maxwell Meng, MD

At the conclusion of these activities, participants will be able to:

1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration.

2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.

3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.

CME Available: auau.auanet.org/node/26067

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Robert Svatek, MD

At the conclusion of these activities, participants will be able to:

1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.

2. Describe the mechanism of action of immunotherapy regimens.

3. Identify and manage the adverse events related to these agents.

CME Available: auau.auanet.org/node/26071

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Kelvin Moses, MD

At the conclusion of these activities, participants will be able to:

1. Identify the active agents and their mechanism of action in the management of metastatic HSPC.

2. Describe the risks and benefits of treatment for metastatic HSPC.

CME Available: auau.auanet.org/node/26063

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Please enjoy this free lesson of the AUA Update Series Volume 38 Lesson 1: Diagnosis and Management of Pheochromocytoma

Please send any comments to [email protected]

Co-Host: Yair Lotan, MD

At the conclusion of these activities, participants will be able to:

1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs.

2. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

CME Available: auau.auanet.org/node/26083

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Take Home Messages in Pediatrics:

Mark Faasse, MD MPH